➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Medtronic

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,041,044

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,041,044
Title:Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
Abstract: As demonstrated herein, a preferential and progressive expansion of a subset of hematopoietic cells bearing somatic mutations in TET2 leads to pro-inflammatory IL-1.beta. signaling at multiple levels, including increased IL-1.beta. transcription, increased NLRP3 inflammasome-mediated IL-1.beta. secretion, and increased IL-1-Receptor 1-mediated IL-1.beta. signaling. Accordingly, provided herein are compositions, methods, and assays for modulating TET2 mutation-mediated IL-1.beta. (interleukin-1.beta.) proinflammatory activity, particularly when caused by somatic mutations in TET2.
Inventor(s): Walsh; Kenneth (Carlisle, MA), Fuster; Jose (Brighton, MA)
Assignee: TRUSTEES OF BOSTON UNIVERSITY (Boston, MA)
Application Number:15/662,546
Patent Claims:1. A method for treating a subject having a TET2 mutation-mediated cardiometabolic disease or disorder comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a blocking IL-1.beta. inhibitor antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier to a subject having one or more inactivating TET2 mutations in a sub-population of peripheral blood hematopoietic cells.

2. The method of claim 1, wherein at least 2% of the peripheral blood hematopoietic cells have the one or more inactivating TET2 mutations.

3. The method of claim 1, wherein the one or more inactivating TET2 mutations are selected from an S282F mutation in SEQ ID NO: 3, an N312S mutation in SEQ ID NO: 3, an L346P mutation in SEQ ID NO: 3, an S460F mutation in SEQ ID NO: 3, a D666G mutation in SEQ ID NO: 3, a P941S mutation in SEQ ID NO: 3, and a C1135Y mutation in SEQ ID NO: 3.

4. The method of claim 1, wherein the blocking IL-1.beta. inhibitor antibody or antigen-binding fragment thereof is selected from ABT981, APX002, Canakinumab, CDP48, immunereszumab, LY2189102, MEDI8968, and gevokizumab.

5. The method of claim 1, further comprising monitoring hematopoietic cell clonality, IL-1.beta. proinflammatory activity, or a combination thereof following the administration of the inhibitor of TET2 mutation-mediated IL-1.beta. proinflammatory activity.

6. The method of claim 1, further comprising decreasing the number or percentage of hematopoietic cells comprising the one or more TET2 mutations in the subject by performing therapeutic cytapheresis on the subject.

7. The method of claim 1, wherein the subject has a cardiovascular disease or disorder.

8. The method of claim 7, wherein said cardiovascular disease or disorder is selected from the group consisting of; atherosclerosis, hypertension, ischemic heart disease, hypertensive heart disease and pulmonary hypertensive heart disease, valvular disease, cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, and restenosis.

9. A method for treating a subject for cardiometabolic disease, comprising: (a) identifying a subject as having one or more TET2 inactivating mutations in a sub-population of peripheral blood hematopoietic cells, and (b) administering to said subject a therapeutically effective amount of a blocking IL-1.beta. inhibitor antibody or antigen-binding fragment thereof.

10. The method of claim 9, wherein at least 2% of the peripheral blood hematopoietic cells have the one or more inactivating TET2 mutations.

11. The method of claim 9, wherein the one or more inactivating TET2 mutations are selected from an S282F mutation in SEQ ID NO: 3, an N312S mutation in SEQ ID NO: 3, an L346P mutation in SEQ ID NO: 3, an S460F mutation in SEQ ID NO: 3, a D666G mutation in SEQ ID NO: 3, a P941S mutation in SEQ ID NO: 3, and a C1135Y mutation in SEQ ID NO: 3.

12. The method of claim 9, wherein the blocking IL-1.beta. inhibitor antibody or antigen-binding fragment thereof is selected from ABT981, APX002, Canakinumab, CDP48, immunereszumab, LY2189102, MEDI8968, and gevokizumab.

13. The method of claim 9, further comprising monitoring hematopoietic cell clonality, IL-1.beta. proinflammatory activity, or a combination thereof following the administration of the inhibitor of TET2 mutation-mediated IL-1.beta. proinflammatory activity.

14. The method of claim 9, further comprising decreasing the number or percentage of hematopoietic cells comprising the one or more TET2 mutations in the subject by performing therapeutic cytapheresis on the subject.

15. The method of claim 9, wherein the subject has a cardiovascular disease or disorder.

16. The method of claim 9, wherein said cardiovascular disease or disorder is selected from the group consisting of; atherosclerosis, hypertension, ischemic heart disease, hypertensive heart disease and pulmonary hypertensive heart disease, valvular disease, cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, and restenosis.

Details for Patent 10,041,044

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novartis Pharms ILARIS canakinumab INJECTABLE; SUBCUTANEOUS 125319 001 2009-06-17   Start Trial TRUSTEES OF BOSTON UNIVERSITY (Boston, MA) 2036-07-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Johnson and Johnson
AstraZeneca
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.